Vimarsana
Biggest News Aggregation in the World

Exchangeable Notes News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Exchangeable Notes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Exchangeable Notes Today - Breaking & Trending Today

Spectrum Brands Announces Pricing of Private Offering of $300 Million of New Exchangeable Senior Notes - Vimarsana News

Spectrum Brands Announces Pricing of Private Offering of $300 Million of New Exchangeable Senior Notes

Spectrum Brands Holdings, Inc. , announced today that its wholly-owned subsidiary, Spectrum Brands, Inc. has priced its private offering of $300 million in aggregate principal amount of its 3.375%...

Spectrum Brands : Form 8-K - MarketScreener - Vimarsana News

Spectrum Brands : Form 8-K - MarketScreener

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT ...

Spectrum Brands Unveils Offering & Share Repurchase Plan - Lululemon Athletica (NASDAQ:LULU), Royal Caribbean Gr (NYSE:RCL) - Vimarsana News

Spectrum Brands Unveils Offering & Share Repurchase Plan - Lululemon Athletica (NASDAQ:LULU), Royal Caribbean Gr (NYSE:RCL)

Spectrum Brands Holdings Inc. (NYSE: SPB) is benefiting from increased pricing, cost improvements and a favorable mix. The company is progressing well with its Global Productivity Improvement Plan, which aims at improving operating efficiency and effectiveness.

Spectrum Brands Announces Proposed Offering of Exchangeable Notes & Share Repurchase Plan - Vimarsana News

Spectrum Brands Announces Proposed Offering of Exchangeable Notes & Share Repurchase Plan

Spectrum Brands Holdings, Inc. , announced today that its wholly-owned subsidiary, Spectrum Brands, Inc. intends to offer, subject to market and other conditions, $300 million in aggregate principal...

Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results - Vimarsana News

Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

--Resubmission of NDA On Track for Early Q2 24— --Cash Runway into 2025, including through Potential FDA Approval in Early Q4 24-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, March 28, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today r

Source: yahoo.com